Sterling Investment Advisors, Ltd. Annovis Bio, Inc. Transaction History

Sterling Investment Advisors, Ltd.

$370 Million
Q3 2024

A detailed history of Sterling Investment Advisors, Ltd. transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Sterling Investment Advisors, Ltd. holds 34,474 shares of ANVS stock, worth $245,110. This represents 0.07% of its overall portfolio holdings.

Number of Shares

34,474

Previous 33,474 2.99%

Holding current value

$245,110

Previous $192,000 44.27%

% of portfolio

0.07%

Previous 0.06%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 24, 2024	BUY	$5.27 - $15.46 $5,270 - $15,460	1,000 Added 2.99%	34,474 $277,000
Q2 2024 Aug 05, 2024	SELL	$4.82 - $18.01 $4,338 - $16,209	-900 Reduced 2.62%	33,474 $192,000
Q2 2023 Aug 03, 2023	BUY	$11.95 - $16.31 $11,950 - $16,309	1,000 Added 3.0%	34,374 $491,000
Q1 2023 Apr 25, 2023	BUY	$12.33 - $22.1 $11,097 - $19,890	900 Added 2.77%	33,374 $514,000
Q3 2022 Nov 03, 2022	BUY	$10.26 - $21.81 $56,430 - $119,955	5,500 Added 20.39%	32,474 $445,000
Q2 2022 Aug 05, 2022	BUY	$8.61 - $13.87 $68,880 - $110,960	8,000 Added 42.16%	26,974 $306,000
Q1 2022 May 03, 2022	BUY	$11.84 - $19.78 $53,280 - $89,010	4,500 Added 31.09%	18,974 $253,000
Q3 2021 Nov 09, 2021	SELL	$30.95 - $120.97 $188,795 - $737,917	-6,100 Reduced 29.65%	14,474 $460,000
Q2 2021 Jul 29, 2021	SELL	$21.55 - $96.1 $239,291 - $1.07 Million	-11,104 Reduced 35.05%	20,574 $1.76 Million
Q1 2021 May 04, 2021	SELL	$8.15 - $38.44 $154,116 - $726,900	-18,910 Reduced 37.38%	31,678 $884,000
Q4 2020 Jan 21, 2021	SELL	$4.36 - $7.54 $1,962 - $3,393	-450 Reduced 0.88%	50,588 $381,000
Q3 2020 Oct 26, 2020	BUY	$3.84 - $6.78 $195,985 - $346,037	51,038 New	51,038 $245,000

Others Institutions Holding ANVS

# of Institutions

Shares Held

1.16M

Call Options Held

229K

Put Options Held

934K

View Full List

About Annovis Bio, Inc.

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $58M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

More about ANVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sterling Investment Advisors, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Sterling Investment Advisors, Ltd. with notifications on news.

Account

Sterling Investment Advisors, Ltd. Annovis Bio, Inc. Transaction History